肝细胞癌相关细胞周期蛋白D1受自噬降解系统选择性调控
研究探讨自噬是否选择性调控细胞周期蛋白D1(cyclin D1)参与肝细胞癌(HCC)发生。在147例HCC患者肿瘤及三种小鼠模型中,低自噬活性与高cyclin D1表达呈负相关,并与患者总生存期差相关。机制上,自噬通过SQSTM1受体选择性降解泛素化cyclin D1,药理学诱导自噬可抑制肿瘤生长。
要点
- 147例HCC患者肿瘤及三种小鼠模型中,低自噬活性与高cyclin D1表达呈负相关,并与总生存期差相关。
- 自噬通过SQSTM1受体介导泛素化cyclin D1选择性招募至自噬体并降解。
- 胺碘酮和雷帕霉素诱导自噬可显著抑制原位肝肿瘤和皮下异种移植瘤生长。
核心结论
- 自噬降解机制与细胞周期调节因子cyclin D1相关联,共同参与HCC肿瘤发生。
- 作者认为这些发现可能对开发HCC患者的替代疗法有价值。
研究设计与样本
- 研究分析了147例HCC患者肿瘤及三种小鼠模型。
- 使用cyclin D1/泛素结合位点(K33-238 R)和磷酸化位点(T286A)突变体、慢病毒介导的ATG5和ATG7沉默以及Sqstm1敲除细胞进行机制验证。
- 通过药理学诱导剂(胺碘酮和雷帕霉素)增加自噬活性,在原位肝肿瘤和皮下肿瘤异种移植模型中评估肿瘤生长。
主要发现
- 在147例HCC患者肿瘤及三种小鼠模型中,低自噬活性与高cyclin D1表达呈负相关,并与HCC患者总生存期差相关。
- 自噬活性增加导致cyclin D1泛素化,并由特定受体SQSTM1介导选择性招募至自噬体,随后与溶酶体融合并降解。
- 自噬选择性降解cyclin D1在细胞增殖、集落形成和肝脏肿瘤形成中发挥抑制作用。
- 药理学诱导剂(胺碘酮和雷帕霉素)增加自噬活性,显著抑制原位肝肿瘤和皮下肿瘤异种移植模型中的肿瘤生长。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Dysfunction of degradation machineries causes cancers, including hepatocellular carcinoma (HCC). Overexpression of cyclin D1 in HCC has been reported. We previously reported that autophagy preferentially recruits and degrades the oncogenic microRNA (miR)-224 to prevent HCC. Therefore, in the present study, we attempted to clarify whether cyclin D1 is another oncogenic factor selectively regulated by autophagy in HCC tumorigenesis. Initially, we found an inverse correlation between low autophagic activity and high cyclin D1 expression in tumors of 147 HCC patients and three murine models, and these results taken together revealed a correlation with poor overall survival of HCC patients, indicating the importance of these two events in HCC development. We found that increased autophagic activity leads to cyclin D1 ubiquitination and selective recruitment to the autophagosome (AP) mediated by a specific receptor, sequestosome 1 (SQSTM1), followed by fusion with lysosome and degradation. Autophagy-selective degradation of ubiquitinated cyclin D1 through SQSTM1 was confirmed using cyclin D1/ubiquitin binding site (K33-238 R) and phosphorylation site (T286A) mutants, lentivirus-mediated silencing autophagy-related 5 (ATG5), autophagy-related 7 (ATG7), and Sqstm1 knockout cells. Functional studies revealed that autophagy-selective degradation of cyclin D1 plays suppressive roles in cell proliferation, colony, and liver tumor formation. Notably, an increase of autophagic activity by pharmacological inducers (amiodarone and rapamycin) significantly suppressed tumor growth in both the orthotopic liver tumor and subcutaneous tumor xenograft models. Our findings provide evidence of the underlying mechanism involved in the regulation of cyclin D1 by selective autophagy to prevent tumor formation. CONCLUSION: Taken together, our data demonstrate that autophagic degradation machinery and the cell-cycle regulator, cyclin D1, are linked to HCC tumorigenesis. We believe these findings may be of value in the development of alternative therapeutics for HCC patients. (Hepatology 2018;68:141-154).
引用
- Wu SY, Lan SH, Wu SR, et al. Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system. Hepatology. 2018. PMID: 29328502. doi:10.1002/hep.29781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。